Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase 3 1

Status

Recruiting 6Active not recruiting 3Terminated 2Not yet recruiting 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Plasmablastic Lymphoma 1Multiple Myeloma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × belantamab mafodotin × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

NCT05117008 2025-01-28

EMBRACE

Medical College of Wisconsin

Phase 2 Terminated
1 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡